Value investing message boards image Log on |  Join ($$) Stock market forums image VF "How To" Guide        Welcome, guest! Learn about guest access                       
ValueForum.com Home
• Related Discussion Forum Messages
As a ValueForum member, this section would contain OPHT message board posts where the ticker symbol OPHT has been mentioned by ValueForum members in posts. Learn more about guest access, and benefits of membership -- we hope you will consider joining ValueForum or trying out our service with a 24 hour trial pass.

• Latest OPHT SEC Filings

Filings Format Description Filing Date File/Film Number
8-K  Documents Current report, item 8.01
Acc-no: 0001410939-18-000059 (34 Act)  Size: 62 KB
2018-11-13 001-36080
181175613
SC 13G  Documents Statement of acquisition of beneficial ownership by individuals
Acc-no: 0001104659-18-067368 (34 Act)  Size: 131 KB
2018-11-09 005-87636
181172835
3  Documents Initial statement of beneficial ownership of securities
Acc-no: 0001209191-18-057892 Size: 10 KB
2018-11-09
CT ORDER  Documents Confidential treatment order
Acc-no: 9999999997-18-008924 (34 Act)  Size: 106 KB
2018-11-02 001-36080
181158088
D  Documents Notice of Exempt Offering of Securities, item 06b
Acc-no: 0001410939-18-000057 (33 Act)  Size: 12 KB
2018-11-02 021-324993
181157103
10-Q  Documents   Interactive Data Quarterly report [Sections 13 or 15(d)]
Acc-no: 0001410939-18-000056 (34 Act)  Size: 6 MB
2018-11-02 001-36080
181155619
8-K  Documents Current report, items 2.02 and 9.01
Acc-no: 0001410939-18-000051 (34 Act)  Size: 161 KB
2018-10-31 001-36080
181148652
8-K  Documents Current report, items 1.01, 3.02, 7.01, 8.01, and 9.01
Acc-no: 0001104659-18-064869 (34 Act)  Size: 3 MB
2018-10-31 001-36080
181148643
SC 13G  Documents Statement of acquisition of beneficial ownership by individuals
Acc-no: 0001567619-18-003709 (34 Act)  Size: 82 KB
2018-10-04 005-87636
181107980
8-K  Documents Current report, items 8.01 and 9.01
Acc-no: 0001410939-18-000049 (34 Act)  Size: 59 KB
2018-10-04 001-36080
181106947
More OPHT SEC Filings


Related news from
Wed, 12 Dec 2018
21:05:00 +0000
Ophthotech Announces the Addition of Ophthalmic Industry Leader, Adrienne L. Graves, Ph.D., Former Chief Executive Officer of Santen Inc., to Its Board of Directors
Dr. Graves is well-known in the ophthalmology community and for her successful track record in building organizations and overseeing innovative ophthalmic products through the development, regulatory and commercialization process in the U.S. and globally. “We are excited to welcome Dr. Graves, a highly-respected executive in our industry, to our Board of Directors,” stated Glenn P. Sblendorio, Chief Executive Officer and President of Ophthotech and David R. Guyer, M.D., Executive Chairman of Ophthotech.
Tue, 11 Dec 2018
19:15:04 +0000
How Many Ophthotech Corporation (NASDAQ:OPHT) Shares Do Institutions Own?
Every investor in Ophthotech Corporation (NASDAQ:OPHT) should be aware of the most powerful shareholder groups. Institutions will often hold stock in bigger companies, and we expect to see insiders owning Read More...
Fri, 30 Nov 2018
14:31:02 +0000
Ophthotech (OPHT) Down 21.7% Since Last Earnings Report: Can It Rebound?
Ophthotech (OPHT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Mon, 12 Nov 2018
12:30:00 +0000
Ophthotech Announces Results from Phase 2a Safety Trial of Zimura® in Combination with Lucentis® in Wet Age-Related Macular Degeneration
Ophthotech Corporation (OPHT) today announced the results from its Phase 2a safety trial of Zimura® (avacincaptad pegol), the Company’s complement factor C5 inhibitor, in patients with wet age-related macular degeneration (AMD). This trial was designed to evaluate the safety of different dosage regimens of Zimura combination therapy in wet AMD and was the first in human trial assessing the safety of Zimura 4mg dose in combination with Lucentis® (ranibizumab) 0.5mg, an anti-vascular endothelial growth factor (anti-VEGF). Various dosing regimens of Zimura were administered in combination with Lucentis in patients with wet AMD who have not been previously treated with anti-VEGF drugs.
Sat, 03 Nov 2018
02:16:01 +0000
Edited Transcript of OPHT earnings conference call or presentation 31-Oct-18 12:00pm GMT
Q3 2018 Ophthotech Corp Earnings Call
Thu, 01 Nov 2018
15:03:03 +0000
Ophthotech (OPHT) Q3 Earnings Beat, Gene Therapy in Focus
Ophthotech reports narrower-than-expected loss in the third quarter. It boosts gene therapy pipeline through new agreement and acquisition.
Wed, 31 Oct 2018
11:29:16 +0000
Ophthotech: 3Q Earnings Snapshot
The New York-based company said it had a loss of 41 cents per share. The company's shares closed at $2.26. A year ago, they were trading at $2.31. _____ This story was generated by Automated Insights (http://automatedinsights.com/ap) ...
Wed, 31 Oct 2018
10:35:00 +0000
Ophthotech Reports Third Quarter 2018 Financial and Operating Results
- Conference Call and Webcast to Discuss Q3 2018 Results and Two Pipeline Deals Announced Today -
Wed, 31 Oct 2018
10:32:00 +0000
Ophthotech Expands Gene Therapy Pipeline in Orphan Retinal Diseases with Exclusive Option for Novel Product Candidates to Treat Best Vitelliform Macular Dystrophy (Best Disease)
Ophthotech Corporation (OPHT) announced today that it has entered into an exclusive option agreement with the University of Pennsylvania (Penn) and the University of Florida Research Foundation (UFRF) for rights to negotiate to acquire an exclusive global license to develop and commercialize novel adeno-associated virus (AAV) gene therapy product candidates for the treatment of Best vitelliform macular dystrophy, also known as Best disease. Best disease, which generally affects individuals in both eyes, is an orphan inherited degenerative retinal disease caused by mutations in the BEST1 gene.
Wed, 31 Oct 2018
10:30:00 +0000
Ophthotech Expands Innovative Retinal Disease Pipeline with Acquisition of Versant Ventures’ Inception 4
Ophthotech Corporation (OPHT) announced today that it has acquired Inception 4, Inc., a privately held company backed by Versant Ventures, expanding Ophthotech’s therapeutic pipeline in age-related retinal indications. HtrA1 is potentially implicated in a range of retinal diseases including geographic atrophy, an advanced form of dry age-related macular degeneration (AMD).
Tue, 23 Oct 2018
11:30:00 +0000
Ophthotech Corporation to Report Third Quarter 2018 Financial Results and Host Conference Call on Wednesday, October 31, 2018
Ophthotech Corporation today announced that it will report its third quarter 2018 financial and operating results on Wednesday, October 31, 2018. Following the announcement, Ophthotech’s management team will host a live conference call and webcast at 8:00 a.m.
Mon, 15 Oct 2018
11:50:00 +0000
Investor Expectations to Drive Momentum within Echo Global Logistics, Sanderson Farms, Ophthotech, CarGurus, Avon Products, and Kemet — Discovering Underlying Factors of Influence
NEW YORK, Oct. 15, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Thu, 04 Oct 2018
11:30:00 +0000
Ophthotech Completes Patient Recruitment As Planned for its Phase 2b Clinical Trial of Zimura® Monotherapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
Ophthotech Corporation (OPHT) announced completion of patient recruitment for its Phase 2b clinical trial of Zimura® (avacincaptad pegol), the Company’s complement factor C5 inhibitor, monotherapy in patients with geographic atrophy secondary to dry age-related macular degeneration (AMD). A total of 286 patients have been enrolled into this randomized, double-masked, sham controlled multi-center clinical trial. This clinical trial is designed to assess the safety and efficacy of various Zimura dosing regimens over 12 months.
Wed, 03 Oct 2018
11:30:00 +0000
Ophthotech Corporation to Present at Chardan’s 2nd Annual Genetic Medicines Conference
Ophthotech Corporation (OPHT) announced today that Keith Westby, Chief Operating Officer, will present an overview of the Company at Chardan’s 2nd Annual Genetic Medicines Conference, on Tuesday, October 9, 2018 at 8:30 a.m. Eastern Time.
Wed, 12 Sep 2018
19:11:30 +0000
Is Ophthotech Corporation (NASDAQ:OPHT) Attractive At Its Current PE Ratio?
This analysis is intended to introduce important early concepts to people who are starting to invest and want to begin learning about how to value company based on its currentRead More...
Fri, 31 Aug 2018
15:38:03 +0000
Why Is Ophthotech (OPHT) Up 5.8% Since Last Earnings Report?
Ophthotech (OPHT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Wed, 22 Aug 2018
11:30:00 +0000
Scientific Data for Novel Adeno-Associated Virus Gene Therapy in Rhodopsin-Mediated Autosomal Dominant Retinitis Pigmentosa Published in Proceedings of the National Academy of Sciences
Ophthotech Corporation (OPHT) announced today that scientists at the University of Pennsylvania (Penn) and University of Florida published proof-of-concept study results on an adeno-associated virus (AAV) gene therapy product candidate for the treatment of rhodopsin-mediated autosomal dominant retinitis pigmentosa (RHO-adRP) licensed by Ophthotech. In June 2018, Ophthotech announced that it entered into an exclusive global license agreement with the University of Florida Research Foundation and Penn for rights to develop and commercialize this novel AAV gene therapy product candidate for the treatment of RHO-adRP.
Fri, 17 Aug 2018
21:40:41 +0000
Edited Transcript of OPHT earnings conference call or presentation 1-Aug-18 12:00pm GMT
Q2 2018 Ophthotech Corp Earnings Call



"ValueForum is an active, private, online discussion community for stock & bond market investing. In discussion forums divided into finely grained topics, you will find sophisticated investors trading tips, research, and due diligence on value stocks, income investments, forex, market news, and more. Join in - trade ideas, strategies, current news, via our unique message bulletin boards, stock ratings system, and other online tools specifically geared toward our community."

Random member testimonial: "At VF I have met some of the greatest givers from all walks of life and from all parts of the world. I thank each of them for sharing part of their life and knowledge with me." more testimonials »

Email / About | Privacy | Terms of Use | How To / FAQ | Msg Ticker | VF Home | My.vf | BDCs.vf | Energy.vf | REITs.vf | TA.vf
 
Nothing in ValueForum.com is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by ValueForum.com. ©2003 - 2018, Powered in part by Ticker TechnologiesContact Us

Stock Market Investing Forum - Trading Tips & Research - Online Message Boards